COMP <GO>
SIBN vs MRK // FREE CASH FLOW YIELD
SI-BONE Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: SIBN 4
— MRK 7
▲ FREE CASH FLOW YIELD LEADER: MRK
LAST: $21.23 (-5.27%) • MKT CAP: $1.00B
fcf-yield
-0.90%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
fcf-yield
3.42%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SIBN VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SIBN | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 79.60% | 74.80% | +4.80 | SIBN | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -10.30% | 20.70% | -31.00 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield ACTIVE | -0.90% | 3.42% | -4.32 | MRK | /fcf-yield <GO> |
| Operating Margin | -11.10% | 34.30% | -45.40 | MRK | /operating-margins <GO> |
| Net Profit Margin | -9.40% | 28.10% | -37.50 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | 20.20% | 1.30% | +18.90 | SIBN | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 8.73 | 5.19 | +3.54 | SIBN | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 65.9 | 51.7 | +14.20 | SIBN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $1.00B | $361.02B | -$360.02B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SIBN REV | MRK REV | SIBN GROSS % | MRK GROSS % | SIBN FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $200.9M | $65.01B | 79.6% | 74.8% | -$9.1M | $12.36B |
| FY 2024 | $167.2M | $64.17B | 79.0% | 76.3% | -$22.9M | $18.10B |
| FY 2023 | $138.9M | $60.12B | — | — | -$18.7M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SIBN // BETA —
MRK // BETA 0.92